Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug ...

Specific objectives include: to evaluate the efficacy, safety, and acceptability of injectable lenacapavir as an additional PrEP option for populations at substantial risk of HIV infection ...

A significant breakthrough in treating the Human Immunodeficiency Virus came recently with the US Federal Drug Administration approving lenacapavir, a new prototype medication. It uses a unique ...

In parallel, Gilead is also planning to carry out a study of lenacapavir for HIV prevention in men and transgender people who have sex with men. PrEP is already a big market for HIV drugs like its ...

A Guideline Development Group (GDG) meeting at the end of the month aims to establish new guidelines for lenacapavir, a twice ...

so that we can ensure a rapid transition to these voluntary license partners after lenacapavir for PrEP is approved.” Administered via subcutaneous injection every six months, the drug provides ...

WHO is convening a Guideline Development Group (GDG) for the development of new guidelines on the use of injectable lenacapavir as pre-exposure prophylaxis (PrEP) for HIV, and the optimization of HIV ...

A Gilead representative received a standing ovation at AIDS24, held in July in Munich, Germany, after unveiling data from the PURPOSE 1 trial (NCT04994509) of lenacapavir for HIV PReP. In a Phase III ...

The first-of-its-kind Center aims to advance new treatment approaches for patients with RAS mutant cancers Dana-Farber Cancer Institute will launch the Center for RAS Therapeutics, a multidisciplinary ...